Pharmaceutical deal for novel NHS stress urinary incontinence innovation

Medipex provides Seoul-based DC Medical with a range of innovation services including the identification and assessment of investment opportunities.

One such innovation Medipex introduced to DC Medical is a stress urinary incontinence (SUI) novel polyurethane (PU) biomimetic material developed by Prof Christopher Chapple at Sheffield Teaching Hospitals NHS Foundation Trust and Prof Sheila MacNeil at the University of Sheffield. DC Medical obtained global exclusive license to the patent protected innovation and established a company Symimetic Limited in 2017 to take forward the SUI innovation.

Medipex is happy to report that Symimetic has recently signed an exclusive distribution agreement with a medical device subsidiary of one of the biggest pharmaceutical companies in the South Korean market that has an annual revenue of more than £600M.

Symimetic logoThe global SUI market size was £1.1B in 2018 and is expected to grow up to £2.1B in 2025 with a 9.4% CAGR. The biomimetic PU material was developed in response to safety concerns. 

Share this